TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8214649

Group type: EXPERIMENTAL
Intervention: Propofol 1-2 mg/kg for induction and sufentanil 0.03 micrograms.kg-1.min-1 plus propofol 50-200 micrograms.kg-1.min-1 for maintenance (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sufentanil 5 micrograms/kg for induction and propofol 50-200 micrograms.kg-1.min-1 for maintenance (Group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sufentanil 5 micrograms/kg for induction and enflurane for maintenance (Group C)
Number of subjects: 60
Study: 3697322

Group type: EXPERIMENTAL
Intervention: IgE-mediated, food-induced asthma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Food allergy respiratory symptoms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isolated case of cough due to food allergy
Number of subjects: 0
Study: 31667678

Group type: EXPERIMENTAL
Intervention: Disclosure of ring use to male partners
Number of subjects: 2629

Group type: EXPERIMENTAL
Intervention: Male partner attendance at the study clinic
Number of subjects: 2629

Group type: EXPERIMENTAL
Intervention: Supportive male partner
Number of subjects: 2629

Group type: EXPERIMENTAL
Intervention: Unsupportive male partner
Number of subjects: 2629

Group type: EXPERIMENTAL
Intervention: Disclosure of ring use
Number of subjects: 2629

Group type: EXPERIMENTAL
Intervention: Partner attendance at the clinic
Number of subjects: 2629
Study: 29482042

Group type: EXPERIMENTAL
Intervention: Active rTMS applied to the left dorsolateral prefrontal cortex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 0
Study: 27273192

Group type: EXPERIMENTAL
Intervention: 1997 mothers (high-risk pregnancy)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 2015 mothers (first-time mothers)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 120
Study: 24520910

Group type: EXPERIMENTAL
Intervention: DeREACH (intervention consisting of nine home visits and three telephone contacts over six months)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: DeREACH (intervention)
Number of subjects: 138
Study: 22661750

Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation (6 ml kg(‐1) predicted body weight)
Number of subjects: 101

Group type: COMPARATOR
Intervention: High tidal volume ventilation (12 ml kg(‐1) predicted body weight)
Number of subjects: 101
Study: 20200338

Group type: EXPERIMENTAL
Intervention: 30 mg ibudilast
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: 60 mg ibudilast
Number of subjects: 297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Ibudilast (both doses)
Number of subjects: 297
Study: 18155854

Group type: EXPERIMENTAL
Intervention: Positive musical mood induction procedures (MMIP) for EM drinkers
Number of subjects: 160

Group type: COMPARATOR
Intervention: Negative musical mood induction procedures (MMIP)
Number of subjects: 160
Study: 15986348

Group type: EXPERIMENTAL
Intervention: Etanercept treatment
Number of subjects: 180
Study: 12919884

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) at 0.12 mJ/mm(2)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 88
Study: 10329871

Group type: EXPERIMENTAL
Intervention: Orally administered misoprostol (50 micrograms every 4 hours)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Vaginally administered misoprostol (25 micrograms every 4 hours)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Orally administered misoprostol
Number of subjects: 220

Group type: COMPARATOR
Intervention: Vaginally administered misoprostol
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 220
Study: 7562150

Group type: EXPERIMENTAL
Intervention: Compression hip screw
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Vandeputte (VDP) endoprosthesis
Number of subjects: 90
Study: 2007107

Group type: EXPERIMENTAL
Intervention: 3.75 mg hyperbaric bupivacaine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 7.5 mg hyperbaric bupivacaine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 10 mg hyperbaric bupivacaine
Number of subjects: 27
Study: 7039758

Group type: EXPERIMENTAL
Intervention: Colestipol
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (sherbet)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (sherbet) from previous trial
Number of subjects: 38
Study: 31449906

Group type: EXPERIMENTAL
Intervention: Posterior compartment peritonectomy
Number of subjects: 54
Study: 28666476

Group type: EXPERIMENTAL
Intervention: Food insecure adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Food insecure children
Number of subjects: 0
Study: 26580237

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 10194

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 10194

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 10194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10194

Group type: COMPARATOR
Intervention: Non-canagliflozin
Number of subjects: 10194
Study: 24704684

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1.2%/tretinoin 0.025% (Clin‐RA)
Number of subjects: 4550
Study: 22070095

Group type: EXPERIMENTAL
Intervention: Losartan-based antihypertensive therapy
Number of subjects: 8831

Group type: COMPARATOR
Intervention: Atenolol-based antihypertensive therapy
Number of subjects: 8831

Group type: EXPERIMENTAL
Intervention: Alcohol intake > 10 units/week
Number of subjects: 8831

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 8831
Study: 19182047

Group type: COMPARATOR
Intervention: Dancers
Number of subjects: 62

Group type: COMPARATOR
Intervention: Persons with late blindness
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Amputation group
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Immobilization group
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Prosthesis use
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Amputation and immobilization groups
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study: 17697911

Group type: EXPERIMENTAL
Intervention: BIAsp50
Number of subjects: 10

Group type: COMPARATOR
Intervention: BIAsp30
Number of subjects: 10
Study: 15548795

Group type: EXPERIMENTAL
Intervention: Standard therapy plus 2.5% povidone‐iodine every 2 hours for 2 weeks
Number of subjects: 358

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 358
Study: 11676999

Group type: EXPERIMENTAL
Intervention: SEIQoL-DW
Number of subjects: 42

Group type: COMPARATOR
Intervention: SIP
Number of subjects: 42

Group type: COMPARATOR
Intervention: SF-36
Number of subjects: 42
Study: 9625084

Group type: EXPERIMENTAL
Intervention: Parents as agents of change (experimental group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Children as agents of change (control group)
Number of subjects: 60
Study: 17212003

Group type: EXPERIMENTAL
Intervention: Interferon alpha ‐ 2b (Intron‐A) 3 million units (MU) subcutaneously thrice weekly for 6 months
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (not treated with interferon)
Number of subjects: 38
Study: 3124604

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sucralfate 1 g
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30738981

Group type: EXPERIMENTAL
Intervention: Tertile 3 (Gini coefficient >41%)
Number of subjects: 15126

Group type: EXPERIMENTAL
Intervention: Tertile 3 (Gini coefficient >41%) after adjustments
Number of subjects: 15126
Study: 29335048

Group type: EXPERIMENTAL
Intervention: Aloe vera-containing toothpaste
Number of subjects: 40

Group type: COMPARATOR
Intervention: Triclosan toothpaste
Number of subjects: 40
Study: 26717361

Group type: EXPERIMENTAL
Intervention: MTX alone
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: GOM+MTX
Number of subjects: 114

Group type: COMPARATOR
Intervention: RA control
Number of subjects: 114
Study: 22905897

Group type: EXPERIMENTAL
Intervention: Therapist focus on client commitment to change alcohol use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapist focus on client ambivalence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Goal assessment
Number of subjects: 0
Study: 21416235

Group type: EXPERIMENTAL
Intervention: Ningdong granule (NDG) 5 mg/kg/day
Number of subjects: 72

Group type: COMPARATOR
Intervention: Methylphenidate 1 mg/kg/day
Number of subjects: 72
Study: 19196218

Group type: EXPERIMENTAL
Intervention: Telephone interview format
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Paper format
Number of subjects: 1090
Study: 17907390

Group type: EXPERIMENTAL
Intervention: Acupuncture + Rehabilitation (Acup + Rehab)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Rehabilitation (Rehab)
Number of subjects: 40
Study: 15066971

Group type: EXPERIMENTAL
Intervention: Evidence based training session on the risks associated with baby walkers
Number of subjects: 0
Study: 12575494

Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Haloperidol (3 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg)
Number of subjects: 20
Study: 9679365

Group type: EXPERIMENTAL
Intervention: Amphetamine
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 7851625

Group type: EXPERIMENTAL
Intervention: Single dose of 131I adjusted to the patients' thyroid weight (group 1)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Repeated lower dose of 131I (approximately 30Gy) (group 2)
Number of subjects: 285
Study: 2697627

Group type: EXPERIMENTAL
Intervention: K-canrenoate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spironolactone
Number of subjects: 0
Study: 61564

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of urea, saline, and sodium bicarbonate; oral water load
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 4
Study: 31606448

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) 20-min daily stimulation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) 2×20-min daily stimulation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 70
Study: 31706325

Group type: EXPERIMENTAL
Intervention: Motor imagery training (EG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gait exercises (CG)
Number of subjects: 40
Study: 28152167

Group type: EXPERIMENTAL
Intervention: Observational Pain Management Protocol
Number of subjects: 128

Group type: COMPARATOR
Intervention: Usual pain management strategies
Number of subjects: 128
Study: 25823271

Group type: EXPERIMENTAL
Intervention: Psychotherapy in addition to medical therapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Medical therapy only (Control Group 2)
Number of subjects: 75
Study: 23604578

Group type: EXPERIMENTAL
Intervention: Movement duration of 1,250 ms
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Movement durations deviating from 1,250 ms
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Movement duration
Number of subjects: 10
Study: 21484319

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 80
Study: 19151052

Group type: COMPARATOR
Intervention: Normal tracheal tube orientation
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Reverse tracheal tube orientation
Number of subjects: 200
Study: 17674576

Group type: EXPERIMENTAL
Intervention: whirlpool tub, jets on, using standard soap products
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: ultrasound tub, ultrasound on, using standard soap products
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: ultrasound tub, ultrasound on, using specialized soap and skin conditioner
Number of subjects: 31

Group type: COMPARATOR
Intervention: either tub (randomized), water circulation off, using standard soap products
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: ultrasound tub using enhanced skin cleansers
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: ultrasound and whirlpool tubs
Number of subjects: 31
Study: 15104658

Group type: EXPERIMENTAL
Intervention: Granulocyte apheresis (GA-1) after initial mobilization with glycosylated G-CSF 6.0 micro g per kg and oral dexamethasone (DXM, 8 mg)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Granulocyte apheresis (GA-2) after remobilization with DXM
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Remobilization with DXM 8 mg
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Remobilization with DXM 4 mg
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Remobilization with DXM 1.5 mg
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo (no remobilization)
Number of subjects: 111
Study: 11844120

Group type: EXPERIMENTAL
Intervention: Peak flow monitoring (PFM)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Symptom-based action plans
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Both groups (PFM and symptoms)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: All subjects with ED visits
Number of subjects: 134
Study: 9781831

Group type: EXPERIMENTAL
Intervention: 75 mg aspirin/day
Number of subjects: 56160

Group type: EXPERIMENTAL
Intervention: Aspirin (30-300 mg/day)
Number of subjects: 56160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56160

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 56160

Group type: COMPARATOR
Intervention: Oral anticoagulants
Number of subjects: 56160
Study: 17974384

Group type: EXPERIMENTAL
Intervention: Combination of 0.25 mcg/day 1‐alpha‐OHD3 plus 10 mcg/day 24,25(OH)2D3
Number of subjects: 46

Group type: COMPARATOR
Intervention: 1‐alpha‐OHD3 plus placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 1‐alpha‐OHD3 plus 24,25(OH)2D3
Number of subjects: 46
Study: 2681316

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.3 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 1.0 mg/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 823516

Group type: EXPERIMENTAL
Intervention: Disodium etidronate (EHDP)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 31678965

Group type: EXPERIMENTAL
Intervention: Pedometer
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitoring (HBPM)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Pedometer + HBPM
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study: 30137352

Group type: EXPERIMENTAL
Intervention: CT-P13 (biosimilar of infliximab)
Number of subjects: 810
Study: 27651353

Group type: EXPERIMENTAL
Intervention: Intravenous ketoprofen
Number of subjects: 477

Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 477
Study: 26152411

Group type: EXPERIMENTAL
Intervention: Imidacloprid 10 % (w/w)/flumethrin 4.5 % (w/w) collar (Seresto)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluralaner (Bravecto) (dosage 25.1 - 49.4 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-treated controls
Number of subjects: 0
Study: 23745274

Group type: EXPERIMENTAL
Intervention: NDT intervention (once per week from corrected age 1 month to 3 months, and 3 to 5 times per week for the following 9 months)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: NDT intervention
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control group (family intervention such as massage and exercise based on early education)
Number of subjects: 203
Study: 21292633

Group type: EXPERIMENTAL
Intervention: 13‐cis‐retinoic acid (13‐cRA)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study: 19735513

Group type: EXPERIMENTAL
Intervention: High flavanol (HF) chocolate, 20 g daily for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low flavanol (LF) chocolate, 20 g daily for 12 weeks
Number of subjects: 30
Study: 17023228

Group type: EXPERIMENTAL
Intervention: Controlled-release carvedilol (CR) 20 mg once daily
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Immediate-release carvedilol (IR) 6.25 mg twice daily
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Controlled-release carvedilol (CR) 80 mg once daily
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Immediate-release carvedilol (IR) 25 mg twice daily
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Controlled-release carvedilol (CR)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Immediate-release carvedilol (IR)
Number of subjects: 122
Study: 15931649

Group type: EXPERIMENTAL
Intervention: Intraperitoneal urokinase 60,000 IU
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 12811716

Group type: EXPERIMENTAL
Intervention: Bedside ultrasound performed by emergency physicians (EPs) after water ingestion in the right lateral decubitus (RLD) position
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bedside ultrasound performed by emergency physicians (EPs) before water ingestion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bedside ultrasound performed by emergency physicians (EPs) in the supine position
Number of subjects: 20
Study: 10357953

Group type: EXPERIMENTAL
Intervention: recombinant follicle stimulating hormone (rFSH)
Number of subjects: 30

Group type: COMPARATOR
Intervention: urinary follicle stimulating hormone (uFSH)
Number of subjects: 30
Study: 8569230

Group type: EXPERIMENTAL
Intervention: Ajmaline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disopyramide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adenosine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Norepinephrine (NE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1904183

Group type: EXPERIMENTAL
Intervention: Naproxen 250 mg thrice daily for 4 weeks postoperatively
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 7205244

Group type: EXPERIMENTAL
Intervention: Social skills training with nonprofessional therapists
Number of subjects: 16

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Inert placebo
Number of subjects: 16
Study: 28657333

Group type: EXPERIMENTAL
Intervention: 60-minute intervention session
Number of subjects: 16

Group type: COMPARATOR
Intervention: Theory-based time-and-attention control session focused on diet and nutrition
Number of subjects: 16
Study: 27632816

Group type: COMPARATOR
Intervention: Pre-invitation leaflet and online booking
Number of subjects: 20905

Group type: EXPERIMENTAL
Intervention: Vaginal self-sampling kits (SSKs) sent unrequested
Number of subjects: 20905

Group type: EXPERIMENTAL
Intervention: Timed appointments
Number of subjects: 20905

Group type: EXPERIMENTAL
Intervention: Offer of a nurse navigator (NN)
Number of subjects: 20905

Group type: EXPERIMENTAL
Intervention: Vaginal self-sampling kits (SSKs) on request
Number of subjects: 20905

Group type: EXPERIMENTAL
Intervention: Choice between a NN or a SSK
Number of subjects: 20905

Group type: EXPERIMENTAL
Intervention: HPV vaccination
Number of subjects: 20905

Group type: EXPERIMENTAL
Intervention: Health economic analysis of timed appointments and unsolicited SSKs
Number of subjects: 20905
Study: 23486755

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral training and automated phone calls (6 sessions, 90 mins each, weekly; phone calls twice daily for 1 year)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study: 24429855

Group type: EXPERIMENTAL
Intervention: Preoperative antiseptic treatment of the operative field
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Double antiseptic washing of the nasopharynx
Number of subjects: 202
Study: 20795423

Group type: EXPERIMENTAL
Intervention: Health education workshop
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 210
Study: 18492760

Group type: EXPERIMENTAL
Intervention: Preoperative octreotide treatment (20 mg im every 28th day for 6 months)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Direct surgery
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Preoperative octreotide treatment (20 mg im every 28th day for 6 months) in patients with macroadenomas
Number of subjects: 62

Group type: COMPARATOR
Intervention: Direct surgery in patients with macroadenomas
Number of subjects: 62
Study: 16517952

Group type: EXPERIMENTAL
Intervention: Single-valve device
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Positive-pressure-valve device flushed with heparinized saline
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Positive-pressure-valve device flushed with saline
Number of subjects: 360

Group type: COMPARATOR
Intervention: Standard device
Number of subjects: 360
Study: 12975720

Group type: EXPERIMENTAL
Intervention: [(14)C]M100240 (25 mg, 50 microCi) as an oral solution under fasting conditions
Number of subjects: 0
Study: 10753272

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic foot compression (IPC(foot)) for >4 hr/d for 4.5 months (group 1)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 37
Study: 8652872

Group type: EXPERIMENTAL
Intervention: Otoscopic exam and refit procedure
Number of subjects: 316

Group type: COMPARATOR
Intervention: Probe refit procedure
Number of subjects: 316
Study: 1422658

Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Number of subjects: 61
Study: 2856708

Group type: EXPERIMENTAL
Intervention: verapamil + propranolol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: propranolol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14